Use access key #2 to skip to page content.
$1.26 0.05 (4.13%)
10/10/2008 3:59 PM

Dynavax Technologies Corp (DVAX)

CAPS Rating:
****

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

DVAX doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

64 Outperforms
6 Underperforms
 

All-Stars

14 Outperforms
1 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on DVAX are also bullish on:

Members bearish on DVAX are also bearish on:

Ticker Tags

Micro Cap (4824), Drug Manufacturers - Other (105)
Suggest a tag

Dynavax Technologies Corp At A Glance

Current Price: $1.26
Last Trade Time: 10/10/2008 3:59 PM
Open: $1.21
Previous Close: $1.21
Daily Range: $1.09 - $1.28
52-Week Range: $0.97 - $6.55
Volume: 1,079,575
Market Cap: $48.96M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

DVAX VS S&P 500 (SPY)

DVAX 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for DVAX

More Headlines...

Top Bull Pitch

Recs

1

Dynavax Technologies Corp (DVAX)

Avatar foolphighter (< 20) Submitted: 1/12/07 2:11 AM

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications. The stock took a large hit Jan. 8th when its TOLAMBA allergy drug failed to show therapeutic bene...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 17 :   1 2 3 4 Next »

Recs

0

 (DVAX)

Avatar wontfindaname (< 20) Submitted: 3/18/08 5:49 PM : Outperform Start Price: $2.46 DVAX Score: -11.52

Expect the huge gap to get filled over the next few days and a slow rise back to 6 over the next couple of months.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DVAX)

Avatar sweetwilliam3 (< 20) Submitted: 3/02/07 4:36 PM : Outperform Start Price: $4.62 DVAX Score: -36.89

Interesting small biostock. I like the TLR technology approach in terms on inate immune response, looks promising. Recent small setback w/ TOLAMBA isn't really that bad. Hepislav looks very promising. Could be a buy out target for big pharma (the TLR technology and their ISS tech. is very intriguing - and better still, looks like it works!)...

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DVAX)

Avatar uberpaige (67.81) Submitted: 2/26/07 2:12 PM : Outperform Start Price: $5.20 DVAX Score: -36.82

another hope for quick accuracy points.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (DVAX)

Avatar foolphighter (< 20) Submitted: 1/12/07 2:11 AM : Outperform Start Price: $6.02 DVAX Score: -41.34

Small biotech has recently released promising late stage trial results for its HEPLSAV hepatitus B vaccine drug, as well as encouraging earlier stage results for its TLR9 agonist in cancer indications. The stock took a large hit Jan. 8th when its TOLAMBA allergy drug failed to show therapeutic benefit based on interim analysis, that appears to present a buying opportunity, particularly since the reason for the failure appears to be the lack of clinically significant disease in the study population. Cash of $1.50/share & no debt and the recent filing of a $100M shelf registration suggests the company is well-positioned to leverage its recent progress into further positive developments. the stock appears to offer a reasonable risk/reward after the recent sell-off.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DVAX)

Avatar tekrider (< 20) Submitted: 12/27/06 11:22 AM : Outperform Start Price: $8.98 DVAX Score: -48.01

this company has the best TLR-9 technology and excellent recent clinical trial results on both its allergy program and hepatitis B vaccine program, both of which address large markets.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 17 :   1 2 3 4 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCreditSuiss 82.04 10/03/07 Outperform NS $4.50-72.00%-42.46%-29.54

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners